IS1850B - Kristölluð a-fjölgervingsmynd af indól afleiðu, notkun hennar, aðferð til framleiðslu og lyfjaefnablanda - Google Patents

Kristölluð a-fjölgervingsmynd af indól afleiðu, notkun hennar, aðferð til framleiðslu og lyfjaefnablanda

Info

Publication number
IS1850B
IS1850B IS4401A IS4401A IS1850B IS 1850 B IS1850 B IS 1850B IS 4401 A IS4401 A IS 4401A IS 4401 A IS4401 A IS 4401A IS 1850 B IS1850 B IS 1850B
Authority
IS
Iceland
Prior art keywords
preparation
synthetic image
drug formulations
indole derivative
crystalline poly
Prior art date
Application number
IS4401A
Other languages
English (en)
Other versions
IS4401A (is
Inventor
Denise Harding Valerie
James Macrae Ross
James Ogilvie Ronald
Original Assignee
Pfizer Research And Developement Company, N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10760474&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS1850(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Research And Developement Company, N.V./S.A. filed Critical Pfizer Research And Developement Company, N.V./S.A.
Publication of IS4401A publication Critical patent/IS4401A/is
Publication of IS1850B publication Critical patent/IS1850B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)
IS4401A 1994-08-27 1996-12-19 Kristölluð a-fjölgervingsmynd af indól afleiðu, notkun hennar, aðferð til framleiðslu og lyfjaefnablanda IS1850B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9417310A GB9417310D0 (en) 1994-08-27 1994-08-27 Therapeutic agents
PCT/EP1995/001914 WO1996006842A1 (en) 1994-08-27 1995-05-17 Salts of an anti-migraine indole derivative

Publications (2)

Publication Number Publication Date
IS4401A IS4401A (is) 1996-12-19
IS1850B true IS1850B (is) 2003-02-07

Family

ID=10760474

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4401A IS1850B (is) 1994-08-27 1996-12-19 Kristölluð a-fjölgervingsmynd af indól afleiðu, notkun hennar, aðferð til framleiðslu og lyfjaefnablanda

Country Status (45)

Country Link
US (2) US6110940A (is)
EP (1) EP0776323B1 (is)
JP (1) JP2904588B2 (is)
KR (1) KR100228952B1 (is)
CN (1) CN1066727C (is)
AP (1) AP576A (is)
AT (1) ATE163182T1 (is)
AU (1) AU691005B2 (is)
BG (1) BG61840B1 (is)
BR (1) BRPI9503812B1 (is)
CA (1) CA2198599C (is)
CO (1) CO4410334A1 (is)
CZ (1) CZ287693B6 (is)
DE (1) DE69501620T2 (is)
DK (1) DK0776323T3 (is)
DZ (1) DZ1923A1 (is)
EG (1) EG23822A (is)
ES (1) ES2112650T3 (is)
FI (1) FI113768B (is)
GB (1) GB9417310D0 (is)
GR (1) GR3026475T3 (is)
HR (1) HRP950460B1 (is)
HU (1) HU227822B1 (is)
IL (1) IL115013A (is)
IS (1) IS1850B (is)
LV (1) LV11800B (is)
MA (1) MA23650A1 (is)
MX (1) MX9701538A (is)
MY (1) MY113733A (is)
NO (1) NO311297B1 (is)
NZ (1) NZ288210A (is)
OA (1) OA10600A (is)
PE (1) PE41596A1 (is)
PL (1) PL180867B1 (is)
RO (1) RO116400B1 (is)
RU (1) RU2159241C2 (is)
SA (1) SA95160156B1 (is)
SI (1) SI9520091B (is)
SK (1) SK282922B6 (is)
TN (1) TNSN95092A1 (is)
TR (1) TR199501061A2 (is)
UA (1) UA45980C2 (is)
WO (1) WO1996006842A1 (is)
YU (1) YU49287B (is)
ZA (1) ZA957142B (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
GB9714081D0 (en) * 1997-07-03 1997-09-10 Pfizer Ltd Pharmaceutical compositions
WO1999001135A1 (en) * 1997-07-03 1999-01-14 Pfizer Limited Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
GB0008563D0 (en) 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US20030166704A1 (en) * 2000-12-20 2003-09-04 Pfizer Inc. New process
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
BRPI0409127A (pt) 2003-04-11 2006-03-28 Pfizer combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
EP1896002A4 (en) * 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
DE602007013440D1 (de) * 2006-10-19 2011-05-05 Auspex Pharmaceuticals Inc Substituierte indole
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
EP1956018A1 (de) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung eines Benzimidazolderivats
EP2093225A1 (en) * 2007-05-01 2009-08-26 Plus Chemicals B.V. Process for preparing crystalline eletriptan hydrobromide form ß
WO2008150500A1 (en) * 2007-05-29 2008-12-11 Plus Chemicals, S.A. A process for preparing 5-bromo-3-[(r)-1-methyl-pyrrolidin-2-ylmethyl]-1h-indole
EP2225224A2 (en) * 2007-12-17 2010-09-08 Actavis Group PTC EHF Novel hemioxalate salt of eletriptan
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
WO2010015692A2 (en) * 2008-08-07 2010-02-11 Biovail Laboratories International Srl Bupropion hydrobromide polymorphs
WO2010097703A1 (en) * 2009-02-25 2010-09-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (en) * 2009-06-25 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of eletriptan and its salt thereof
US8754239B2 (en) 2010-01-19 2014-06-17 Sms Pharmaceuticals Limited Process for preparing eletriptan hydrobromide having α-form
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
WO2017125351A1 (en) 2016-01-21 2017-07-27 Laboratorios Lesvi Sl Process for preparing (( r)-3-[(-1-methylpyrrolidin-2-yl)methyl]-5-(2-phenylsulfonylethyl)-1h-indole

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
AU651637B2 (en) * 1990-10-15 1994-07-28 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5208248A (en) * 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
HUT69705A (en) * 1991-11-25 1995-09-28 Pfizer Indole derivatives
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (is) * 1992-03-05 1996-10-11 Pfizer
CZ281763B6 (cs) * 1992-04-07 1997-01-15 Pfizer Inc. Indolové deriváty představující 5-HT1 agonisty, způsob jejich přípravy, farmaceutické prostředky obsahující tyto látky, jejich použití a meziprodukty postupu přípravy
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
SK278182B6 (en) * 1992-04-10 1996-03-06 Pfizer Acylaminoindole derivatives as 5-ht1 agonists, method of their preparation and pharmaceutical compositions containing these matters their use and semifinished products of preparation proces
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
EP0695301B1 (en) * 1993-04-22 1996-10-30 Pfizer Limited Indole derivatives as 5-ht1-like agonists for use in migraine
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
HUT75646A (en) * 1993-08-31 1997-05-28 Pfizer 5-arylindole derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
SI9520091A (sl) 1998-02-28
SA95160156B1 (ar) 2005-05-30
YU56995A (sh) 1998-07-10
TR199501061A2 (tr) 1996-06-21
BRPI9503812B1 (pt) 2017-04-18
BG61840B1 (bg) 1998-07-31
NO970861L (no) 1997-02-26
HUT77310A (hu) 1998-03-30
EP0776323B1 (en) 1998-02-11
LV11800A (lv) 1997-06-20
WO1996006842A1 (en) 1996-03-07
HRP950460B1 (en) 2000-02-29
CA2198599A1 (en) 1996-03-07
DZ1923A1 (fr) 2002-02-17
LV11800B (en) 1997-10-20
US6380226B1 (en) 2002-04-30
MA23650A1 (fr) 1996-04-01
ATE163182T1 (de) 1998-02-15
IL115013A (en) 2000-11-21
DE69501620T2 (de) 1998-07-02
ES2112650T3 (es) 1998-04-01
BG101250A (en) 1997-09-30
MY113733A (en) 2002-05-31
US6110940A (en) 2000-08-29
RU2159241C2 (ru) 2000-11-20
NO311297B1 (no) 2001-11-12
CO4410334A1 (es) 1997-01-09
PE41596A1 (es) 1996-10-12
AP576A (en) 1997-03-20
GB9417310D0 (en) 1994-10-19
JP2904588B2 (ja) 1999-06-14
ZA957142B (en) 1997-02-25
HU227822B1 (en) 2012-03-28
KR100228952B1 (ko) 1999-11-01
IL115013A0 (en) 1995-12-08
PL318319A1 (en) 1997-06-09
BR9503812A (pt) 1996-04-16
CZ56397A3 (cs) 1998-05-13
NO970861D0 (no) 1997-02-26
PL180867B1 (pl) 2001-04-30
FI970800A (fi) 1997-02-26
AU2735295A (en) 1996-03-22
TNSN95092A1 (fr) 1996-02-06
GR3026475T3 (en) 1998-06-30
FI113768B (fi) 2004-06-15
CN1066727C (zh) 2001-06-06
CZ287693B6 (en) 2001-01-17
FI970800A0 (fi) 1997-02-26
HRP950460A2 (en) 1997-08-31
JPH09512283A (ja) 1997-12-09
DE69501620D1 (de) 1998-03-19
KR970705557A (ko) 1997-10-09
EG23822A (en) 2007-09-19
SK24897A3 (en) 1998-08-05
EP0776323A1 (en) 1997-06-04
MX9701538A (es) 1997-05-31
AU691005B2 (en) 1998-05-07
SI9520091B (sl) 2004-10-31
AP9500754A0 (en) 1995-07-31
CN1155886A (zh) 1997-07-30
DK0776323T3 (da) 1998-03-30
YU49287B (sh) 2005-03-15
NZ288210A (en) 1998-01-26
RO116400B1 (ro) 2001-01-30
IS4401A (is) 1996-12-19
SK282922B6 (sk) 2003-01-09
CA2198599C (en) 2000-06-06
OA10600A (en) 2000-04-06
UA45980C2 (uk) 2002-05-15

Similar Documents

Publication Publication Date Title
IS1850B (is) Kristölluð a-fjölgervingsmynd af indól afleiðu, notkun hennar, aðferð til framleiðslu og lyfjaefnablanda
NO996433L (no) Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav
NO20000227L (no) Krystallmodifikasjon av et N-fenyl-2-pyrimidinaminderivat, fremgangsmåte for dens fremstilling og dens anvendelse
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
NO307335B1 (no) Substituerte N-(indol-2-karbonyl)-<beta>-alaninamider, anvendelse derav og farmasøytisk preparat
NO993676L (no) FremgangsmÕte for fremstilling og rensing av et N-alkylert aspartamderivat
DK1036794T3 (da) 2-Aryl-8-oxodihydropurinderivater, fremgangsmåde til fremstilling af samme, medicinske præparater indeholdende samme og mellemprodukter deraf
NO942316D0 (no) Isatinderivater, fremgangsmåter for deres fremstilling og farmasöytisk preparat omfattende slike derivater
NO974965D0 (no) Fremgangsmåter og formuleringer for modulering av den humane seksualrespons
DK0785770T3 (da) Sammensætninger til bekæmpelse af hæmorroider og fremgangsmåde til anvendelse deraf
NO306257B1 (no) 11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav
DK1006110T3 (da) Derivater af acylpiperazinylpyrimidiner, fremstilling deraf og anvendelse som lægemidler
NO20003070D0 (no) Substituert tiazolidinderivat, fremgangsmÕte for fremstilling og anvendelse derav
NO307092B1 (no) Sordaridin-derivater, anvendelse derav og farmasoeytisk blanding
DK0480052T3 (da) Quinolinderivat, antiulcus-lægemiddel indeholdende derivatet og fremstilling af derivatet
NO972477D0 (no) Meso-mono-jod substituerte tetramakrocykliske forbindelser og fremgangsmåter for fremstilling og anvendelse
DK3497A (da) Formulering med vedvarende frigivelse af et animalsk væksthormon og fremgangsmåde til fremstilling deraf
DK1003383T3 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
NO305804B1 (no) Krystallinsk maltitolblanding og fremstilling derav
DK0994706T3 (da) Præparater til oral indgivelse af taxaner og anvendelse deraf
DK1178799T3 (da) Gastrobeskyttede mikrogranula, fremgangsmåde til opnåelse af samme og farmaceutiske præparater
DK0925292T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af substituerede chromanolderivater
NO20002526D0 (no) Mellomprodukt med høyt legemiddelinnhold og orale doseringspreparater med modifisert frigivelse samt fremgangsmÕter for fremstilling derav
DK0983249T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater
NO932912D0 (no) Preparat og fremgangsmaater til generering av ben